Skin Analytics’ Post

Hi folks, in a significant advancement in medical technology, the FDA has approved the first AI-powered device capable of detecting all three common types of skin cancer - basal cell carcinoma, squamous cell carcinoma, and melanoma. This handheld device, developed by DermaSensor, represents a major leap forward in non-invasive, real-time cancer detection. ● Innovative AI Technology: Utilizes advanced spectroscopy and an FDA-cleared algorithm for unbiased, rapid evaluation of suspicious skin lesions. ● Impressive Clinical Performance: Demonstrated a 96% sensitivity across 224 skin cancer cases in an FDA study, with a 97% likelihood of accurately identifying benign lesions. ● Enhancing Physician Accuracy: In clinical trials, it effectively reduced missed cancer cases, boosting diagnostic confidence. ● Streamlining Patient Care: This tool is expected to improve coordination between primary care and dermatology, leading to quicker, more accurate referrals. The integration of AI in healthcare, especially in early cancer detection, is a game-changer. This device not only aids primary care physicians but also represents a collaborative step forward with dermatologists. It's a prime example of how technology can transform healthcare efficiency and patient outcomes. For more info, read the full article 👇 https://cstu.io/99b9d9 #AIDiagnostics #HealthcareInnovation #SkinCancerDetection #MedicalTechnology #HealthTech #ArtificialIntelligence #EmbeddedRecruiter #RunTimeRecruitment

18% or fewer of stage I / II melanomas actually progress to metastatic disease. Yet the majority of deaths from #melanoma occur in this group. All patients are treated as having the same risk for progression because it is only possible to identify whose melanoma will progress by using additional biomarkers not yet available in the UK. Following removal of the melanoma and surrounding skin, the UK follow-up schedule for all patient usually comprises: -         Stage 1A: 2-4 times for the first year then every 6 months for 2 years. -         Stages 1B to 2B: every 3 months for the first 3 years, then every 6 months for the next 2 years. There is an urgent need for better risk stratification of melanomas to identify and spare the 90% of patients presenting with early-stage, low-risk melanomas from the burden of standard follow-up protocols and reduce unnecessary pressure on the healthcare system. #AMBLor is our prognostic risk stratification technology that accurately identifies early-stage, low-risk melanomas. The immunohistochemical assay uses two monoclonal antibodies that recognise the proteins AMBRA1 and loricrin in the epidermis covering the melanoma tumour. If the biomarker proteins are present, the melanoma is at low risk of progression. If one or both proteins are absent, the melanoma is classified as at-risk. Patients stratified as low risk by AMBLor may not require sentinel lymph node biopsy and could benefit from reduced frequency of follow ups. Personalising patient follow-up schedules could: - Reduce overall healthcare costs, by reducing the number of appointments and imaging scans - Enable clinicians to focus on at-risk people - Help alleviate anxiety and the burden of follow-up www.amlo-biosciences.com AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. The AMBRA1 and loricrin test is available in the UK as a UKAS accredited LDT. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers  

Continuing the streak of fabulous news from our current and alumni companies, a huge congratulations to Enspectra Health, Inc. for receiving FDA Breakthrough Device Designation for the VIO™ Skin Platform for the evaluation of lesions suspicious of basal cell carcinoma and squamous cell carcinoma in select high risk populations. The next generation, AI-powered platform integrates the FDA-cleared VIO technology with VIO.ai NMSC, a CADx/CADt (Computer-Aided Diagnosis and Triage) software function that classifies lesions to aid physicians in their clinical decision-making. "Attaining breakthrough designation for our next generation technology underscores the need for a non-invasive assessment option in non-melanoma skin cancer," said Gabriel Sanchez, Ph.D., CEO and co-founder of Enspectra Health. "We are honored to work closely with the FDA to bring advanced AI/ML tools to dermatology for better patient care." #healthtech #digitalhealth #innovation #skincancer

DermaSensor, Inc. 's handheld AI device gets the FDA green light! This tech marvel is set to transform skin cancer detection. 🔍 In #FDA tests, this device spotted 96% of skin cancers. That's not just smart; it's life-saving smart. 💡 How It Works: Shines a light, analyzes cellular patterns, and AI does its magic. 💳 The Deal: It's subscription time – $199/mo for five patients or go unlimited for $399/mo. 🤝 Big Picture: It's not just about spotting cancer. It's about connecting the dots between primary care and dermatology. 🚀 This isn't just a win for DermaSensor; it's a leap for AI in healthcare. 12 years in the making, and we're just getting started. Here's to hoping this paves the way for more AI-driven medical breakthroughs. #HealthTech #AIDiagnosis #SkinCancerAwareness #Dermasensor

Innovations in #gastriccancer treatment, from #precisionmedicine and #immunotherapy to #targetedtherapies and minimally invasive surgery, are revolutionizing patient outcomes. Ongoing research and #advancements in #diagnostic tools signify a transformative era in gastric cancer care. The future promises improved survival rates, personalized #treatments, and hope for those affected #RDive #GastricCancer #CancerTreatment #PrecisionMedicine #Immunotherapy #TargetedTherapies #MinimallyInvasiveSurgery #MedicalAdvancements #HealthcareInnovation #CancerCare #PatientOutcomes #MedicalScience #SurvivalRates #HopeForPatients #DiagnosticAdvancements #GlobalHealth Click to know more:  https://lnkd.in/dtE2NHi9 

FDA approves AI tool for detecting skin cancer. #SkinCancerDetection 🤝 Follow us on Discord 🔜: https://lnkd.in/gt823Zd3 🤝 Follow us on Whatsapp 🔜 https://wapia.in/wabeta _ ❇️ Summary: The FDA has approved an AI-powered device developed by DermaSensor for detecting skin cancer. The device uses light to examine suspicious moles on a cellular level and is specifically marketed for primary care physicians to use in routine check-ups for patients aged 40 and above. This approval provides a new way for physicians to evaluate troubling skin spots and could help in catching skin cancer early, as most types are not deadly when detected early. Hashtags: #chatGPT 1. #AIDetectsSkinCancer 2. #FDAClearsAIforSkinCancer

Today marks the first day of Melanoma and Skin Cancer awareness month. Data from the World Health Organization’s International Agency for Research on Cancer suggests the total number of new  global melanoma cases will reach 413,100 per year by 2030. This will be an increase of more than 27% on the 324,635 cases registered in 2020. As a diagnostics company in this space, we are passionate about routinely checking skin for any changes and being careful in the sun. #Melanoma is more treatable if caught early, and with less than 15% of early-stage melanomas progressing to late stage, this message is even more important. Find out more about our prognostic technology #AMBLor that uses biomarkers loricrin and AMBRA1 to accurately identify early-stage melanomas that are at low risk of progression and what this can mean to melanoma management: www.amlo-biosciences.com Keep an eye on our social channels over May for more information on the impact of melanoma and how you can be #skinaware. The AMBLor® technology is only used in the USA as in a laboratory-developed test (LDT) provided by Avero Diagnostics. Avero’s AMBLor melanoma test has not been reviewed by the US FDA. An AMBLor test is not yet available in the UK. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

Learn about the physical attributes of your Skin Mole and understand whether it is benign or malignant.  We look for any signs of Skin Cancer and aid in effective and early diagnosis using all three modalities of Blood Tests, Biopsies and Molecular Specialised Tests at Ganesh Diagnostic. Learn more. https://rb.gy/u601r5 To know more call at 011-47-444-444, #cancer #health #radiology #pathology #skincancer #biopsies #molecular 

Hot off the press! We are delighted to share our recent study on the expression characteristics of Nectin-4 in a subset of cutaneous adnexal neoplasms. Enfortumab vedotin (EV) is an FDA-approved antibody-drug conjugate targeting Nectin-4 for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have previously undergone immune checkpoint inhibitor and platinum-containing chemotherapy. According to our findings, EV could potentially serve as a therapeutic option for patients with advanced adnexal carcinomas. Feel free to explore the details if you have an interest in dermatopathology and IHC pathology [PMID: 38200650]! 😆🔬#pathology #dermatopathology #immunohistochemistry

🗞 IN THE NEWS: A joint effort between researchers with the National Cancer Institute (NCI) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has revealed that a benign nail condition known as onychopapilloma may lead to the diagnosis of BAP1 tumor predisposition syndrome. ➡ Read more: https://lnkd.in/eeXnZpdz #CancerResearch #Innovation #Health #Medicine